Peer Reviewed
Rheumatology clinic

Rofecoxib: the second COX-2 specific inhibitor

Julien P De Jager
Abstract
A new class of anti-inflammatory agents, the COX-2 specific inhibitors, has only recently become available in Australia. In this article, Dr de Jager discusses what is known about rofecoxib, the newest agent in the class.
Key Points
    What is rofecoxib?

    Rofecoxib (Vioxx) is an anti-inflammatory analgesic that belongs to a new class of agents called coxibs, selective inhibitors of the cyclo-oxygenase-2 (COX-2) enzyme. Rofecoxib is now available on private script.

    The first coxib to become available, celecoxib (Celebrex), has had remarkable acceptance by the public and the medical profession through a combination of good marketing and poor press for the predecessors, conventional NSAIDs. There would be very few GPs who have not already prescribed or used celecoxib.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?